Kornimate/medical-research-clean huggingface dataset:
memo-medical marijuana and opioids study

Conditions: Opioid Use; Marijuana; Chronic Pain; HIV/AIDS

Summary: the study will examine how medical cannabis use affects opioid analgesic use over time, with particular attention to thc/cbd content, hiv outcomes, and severe adverse events.

the overarching goal of the study is to understand how medical cannabis use affects opioid analgesic use over time, with particular attention to thc/cbd content, hiv outcomes, and adverse events. the study will include a cohort of 250 hiv+ and hiv- adults with (a) severe or chronic pain, (b) opioid analgesic use, and (c) new certification for medical cannabis. over 18 months, participants will have 7 in-person visits every 3 months and 39 web-based questionnaires every 2 weeks. data sources will include questionnaires; medical, pharmacy, and prescription monitoring program records; and urine and blood samples. over each 2-week time period (unit of analysis), the primary exposure measure will be number of days of medical cannabis use, and the primary outcome measure will be cumulative opioid analgesic dose. qualitative interviews will also be conducted with a subgroup of 30 participants to explore perceptions of how medical cannabis use affects opioid analgesic use. qualitative findings will help understand the reasons underlying the findings of the cohort study.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * english or spanish fluency * new certification for medical cannabis within 90 days * no medical cannabis use in the 6 months prior to certification * medical cannabis qualifying complication of "chronic or severe pain" * use of prescribed or illicit opioid analgesics within 30 days exclusion criteria: * inability to provide informed consent * inability to complete study visits over 18 months * qualifying conditions for medical cannabis in ny that are likely to cause unique pain syndromes (cancer, epilepsy, multiple sclerosis, spinal cord injury, amyotrophic lateral sclerosis, parkinson's disease, inflammatory bowel disease, hungtington's disease) * terminal illness * current or prior psychotic disorder
investigating a well-being review in pulmonary hypertension

Conditions: Pulmnary Hypertension

Summary: pulmonary hypertension (ph) is a rare disease that makes patients easily become breathless. there is evidence that people with ph can benefit from exercise; we want to look at how they can access rehabilitation in their local community. aim: to see if it is feasible to study physiotherapy well-being reviews in ph. step 1: we will interview some patients with ph who have had rehabilitation and ask questions about their experiences. we will also ask what they think we should measure to show any difference their rehabilitation has made to them. the findings from step 1 will help us to shape the details of step 2, where we will conduct a small study to see if it is feasible to run a full study. participants will be divided randomly into a treatment group and a control group. the treatment group will have a physiotherapy well-being review, leading to referral to their most suitable local rehabilitation service and follow-up after 6 months. the control group will receive brief exercise advice and follow-up after 6 months. the findings will help to design a full study and be shared with patients and health professionals.


Eligibility criteria:
inclusion criteria: * in world health organisation (who) functional class ii or iii * have a diagnosis of ph * have started on ph drug therapy in the preceding 18 months * showing no signs of worsening breathlessness or heart failure * on an unchanged ph therapeutic regime for at least 6 months prior to inclusion. exclusion criteria: * have an active infection or acute exacerbation of lung disease * have participated in a clinical study involving another investigation of drug, device or exercise within the previous 6 months * are on a surgical or other pathway of care that has pre-determined physiotherapy or activity regimes or restrictions * have any additional medical conditions that may adversely affect the safety of the subject or severely limit the lifespan of the subject * have participated in rehabilitation in the last 12 months.
femtosecond laser assisted keratotomies for the management of corneal astigmatism

Conditions: Astigmatism; Cataract

Summary: a cataract is a clouding of the lens that occurs naturally with age. cataract surgery involves removal of the cloudy lens and replacement with an artificial one. a special laser (femtosecond laser) is now being used to help make cataract surgery safer and more accurate . the femtosecond laser can also be used to correct astigmatism, an irregular curvature of the cornea, at the time of cataract surgery through a procedure called astigmatic keratotomy (ak). this study is gathering information about the specific laser settings that are used to perform astigmatic keratotomies (ak) during cataract surgery. this information will be used to improve the outcomes of patients that receive cataract surgery with astigmatic keratotomies in the future.


Eligibility criteria:
inclusion criteria: * age: ≥18 years of age * sex: male or female * patients who are planned to undergo femtosecond laser-assisted cataract surgery with astigmatic keratotomy at the schein ernst mishra eye clinic within the next 60 days of their cataract consultation visit. subjects with planned single or bilateral cataract eye surgeries are eligible. planned opposite eye surgery must be within 2-4 weeks of first cataract surgery. * fluent in written and spoken english exclusion criteria: * patients with corneal dystrophies, including anterior basement membrane dystrophy, keratoconus, and fuch's endothelial corneal dystrophy. * age \< 18 years * pregnant women * cognitive impairment * prisoners

Keywords: astigmatism cataract femtosecond laser
epidural analgesia versus iv meperidine for labor pain control

Conditions: Labor Pain

Summary: 60 female that care for pain control during second stage of delivery, will choose between epidural or systemic analgesia. continuous ecg (3 lead)monitoring will be recorded during the second stage for 10 minutes. 30 minutes after administration of either pain relief, a second recording of maternal ecg will take place for 10 minutes.

population 60 female during second stage of delivery * inclusion criteria : all parturients requiring pain relief will choose between systemic or epidural analgesia. * exclusion criteria: all parturients with cardiac disease, neurological disease, endocrine disease, diabetes, hypertension or any parturients being treated with medications that might effect the cardiovascular autonomic system. * method: a 10 minute recording of a 3 lead ecg will be performed during the second stage of the delivery (3-7 cm opening). the parturient will be lying on her left side for that period. * 30 minutes after administration of either epidural or systemic meperidine for pain relief, a second recording of maternal ecg will take place for 10 minutes. * estimated duration of the procedure about one hour per woman.

Eligibility criteria:
inclusion criteria: all parturients requiring pain relief will choose between systemic or epidural analgesia. exclusion criteria: all parturients with cardiac disease, neurological disease, endocrine disease, diabetes, hypertension or any parturients being treated with medications that might effect the cardiovascular or autonomic system. -
abdominal nerve blockade in chronic heart failure.

Conditions: Heart Failure

Summary: patients with chronic heart failure and undergoing right heart catheterization will be enrolled in this study. subjects will undergo catheterization of the heart to obtain central cardiac pressure and other cardiac hemodynamic parameters. subsequently, the subject will undergo a regional nerve block of the splanchnic nerves. this study will be a prospective, uncontrolled clinical trial. the study will not be controlled as invasive monitoring of hemodynamics will be performed, allowing clear demonstration of a cause-effect relationship. the goal of the study is to provide proof of concept. patients will undergo detailed physiological testing.


Eligibility criteria:
inclusion criteria: * diagnosis of heart failure (hf) * symptomatic with dyspnea * on a stable hf drug regimen exclusion criteria: * ongoing treatment with oral anticoagulation other than aspirin * immunosuppressive medications for solid organ transplant * acute mi (stemi or type i nstemi) within 7 days * systolic blood pressure \ 180 mmhg * infiltrative cardiomyopathy or constrictive cardiomyopathy * chronic kidney disease stage 5 * pregnancy
biomonitoring and cardiorenal syndrome in heart failure(bionics-hf) trial

Conditions: Cardiorenal Syndrome; Acute Decompensated Heart Failure

Summary: the purpose of this study is to evaluate the ability of a non-invasive monitor that measures how much fluid is in the body as well as various blood tests for their ability to predict worsening kidney function in patients with heart failure.

our specific aims are to: 1. evaluate the individual and collective ability of pro-b type natriuretic peptide (nt-pro-bnp), soluble (s)st2, neutrophil gelatinase-associated lipocalin (ngal), and bioelectrical impedance vector analysis (biva) for predicting in-hospital worsening renal function (wrf) in patients evaluated in emergency department (ed)with acutely decompensated heart failure (adhf)compared to a model of clinical variables alone. 2. evaluate the individual and collective ability of nt-probnp, sst2, ngal, and biva for identifying the correct cause of in-hospital wrf in patients evaluated in the ed with adhf. 3. evaluate the individual and collective ability of nt-pro-bnp, sst2, ngal, and biva for predicting outcomes (all-cause death, all-cause re-hospitalization, initiation of renal replacement therapy by 180 days) in patients with adhf.

Eligibility criteria:
inclusion criteria: * dyspnea thought to be due to adhf * nyha class iii or iv symptoms exclusion criteria: * renal failure requiring renal replacement therapy rior to enrollment * unable or unwilling to participate * \> 6 hours from first dose of intravenous diuretic
a phase ib/ ⅱ clinical study of mil62 in primary membranous nephropathy

Conditions: Primary Membranous Nephropathy

Summary: this study was divided into two stages. in the first stage (phase ib), 30 subjects were randomly divided into mil62 600mg, mil62 1000mg and cyclosporine groups at a ratio of 1:1:1, with 10 subjects in each group. tolerance to mil62 was evaluated within 4 weeks after the first administration. if the overall safety is determined by the investigator and sponsor to be tolerable to mil62, phase ii enrollment will be initiated. the second stage was also randomly divided into mil62 600mg, mil62 1000mg and cyclosporine groups according to the ratio of 1:1:1, 30 subjects in each group, to evaluate the efficacy of mil62 and cyclosporine in the treatment of primary membranous nephropathy. eligible subjects in both phases received treatment and follow-up for a total of 104 weeks. the 76-week overall response rate was the primary endpoint.


Eligibility criteria:
inclusion criteria: 1. adult patients, ≥18 years of age; 2. diagnosis of primary membranous nephropathy (pmn) according to renal biopsy prior to or during screening； 3. best support for 3 months before the screening and above, 24 hours urinary protein 5 g or higher, or screening best support treatment before 6 months or more, 24 hours urinary protein \> 3.5 g, and urine protein decreased 50% or less, or if it always has the best support after a full course of treatment, 24 hours urinary protein is still more than standard after confirmed by the researchers can into the group; 4. egfr ≥40 ml/min/1.73m\^2 or qualified endogenous creatinine clearance ≥40 ml/min/1.73m\^2 based on 24-hour urine collection during screening； 5. sufficient organ function; 6. able and willing to provide written informed consent and to comply with the study protocol. exclusion criteria: 1. participants with a secondary cause of mn； 2. cyclosporine resistance； 3. urine protein decreased by \> 50% within 6 months before screening； 4. received treatment drugs for membranous nephropathy； 5. concomitant with other serious diseases； 6. received live vaccination, major surgery (other than diagnostic), and participated in other clinical trials within 28 days prior to receiving the first study drug;central nervous system metastasis； 7. infection with human immunodeficiency virus (hiv), hepatitis b or hepatitis c(including hbsag,hbcab positive with abnormal hbv dna or hcv rna ); 8. those who have a clear history of tuberculosis or have received anti-tuberculosis treatment； 9. other exclusion criteria may apply；
study to assess adverse events and compare how crushed, ground, and intact oral tablets venetoclax moves through the body of healthy female adult volunteers

Conditions: Healthy Volunteers

Summary: the objective of this study is to assess the oral bioavailability of crushed and ground venetoclax commercial tablets relative to the intact venetoclax commercial tablets under fed condition in healthy female participants.


Eligibility criteria:
inclusion criteria: * must either be: postmenopausal, permanently surgically sterile, or perimenopausal or premenopausal and practicing a method of birth control until at least 1 month after the last dose of study drug. * a condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ecg). exclusion criteria: * significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, pulmonary or hepatic disease within the past 6 months that in the opinion of the investigator would adversely affect her participating in this study. * history of any clinically significant sensitivity or allergy to any medication or food. * history of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, ph, or absorption.

Keywords: healthy volunteers venetoclax abt-199
the treatment of bronchopulmonary dysplasia by intratracheal instillation of mesenchymal stem cells

Conditions: Safety Issues; Effect of Drugs

Summary: to study the effect and saftey of intratracheal instillation of mesenchymal stem cells for treatment bpd

this is a phase 1 clinical trial that constitues two points cohorts with 100 participants per cohort who will receive instillation dose of mesenchymal stem cells-25 million cells/kg,with ventilation after 14 days.and the placebol will be 0.9% sodium choride. the investigator will proceed the groups during the same period. 1. deographic data and baseline charateristics of the studied groups were collected: gestational age (weeks) birth weight (g) gender cesarean section delivery antenatal steroids prolonged rupture of membrane multiple pregnancies apgar score at 5 minutes 2. mesenchymal stem cels dose is 25 million cells/kg 3. assessment the incidence of bpd after instillation of mesenchymal stem cells 4. the adverse after instillation of mesenchymal stem cells

Eligibility criteria:
inclusion criteria: twenty-eight weeks to thirty-seven weeks prematures who need ventilaton for 14 days after birth, and the oxygen concentration is more than 30% exclusion criteria: preterm infants with major congenital malformations, chromosomal anomalies, inborn errors of metabolism and clinical or laboratory evidence of a congenital infection

Keywords: mesenchymal stem cells safety effect bpd
biomarkers in dermal interstitial fluid for early diagnosis and follow-up of cardiovascular diseases

Conditions: Cardiovascular Diseases

Summary: sampling of disf and blood plasma for qualitative measurements.

sampling of disf will be performed to investigate biomarkers in disf for early diagnosis and follow-up of cardiovascular diseases.

Eligibility criteria:
inclusion criteria: group 1: chronic heart failure with stable therapy. nyha classification iii and iv. age \> 60 years. group 2: age 18-40 years. exclusion criteria: * participating in another clinical investigation which may affect the study outcome according to clinical judgement. * previous use of sampling system used. * pregnancy or lactating. * any disease or condition that may be affected. * individuals who lack the ability to fully consent to participate in the study. * severe skin injury. * tattoo or piercing close to sampling area. * group 1: all forms of emergency care. * group 1: non-stable therapy. * group 1: sepsis. * group 1: bmi \> 30kg/m2. * group 1: age \> 84 years. * group 2: known heart or vascular disease. * group 2: diabetes. * group 2: kidney disease.
a study of bonviva (ibandronate) in women with post-menopausal osteoporosis previously treated with bonviva

Conditions: Post-Menopausal Osteoporosis

Summary: this 2 arm study will assess the long-term efficacy and safety of oral treatment with 100mg or 150mg bonviva in women with post-menopausal osteoporosis who have previously completed bonviva study bm16549 (mobile study). patients will receive bonviva either 100mg po monthly, or 150mg po monthly. patients will also receive daily supplementation with vitamin d and calcium. the anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.


Eligibility criteria:
inclusion criteria: * successful completion of bonviva study bm16549, with at least 75% compliance; * ambulatory. exclusion criteria: * malignant disease diagnosed within the previous 12 years (except basal cell cancer that has been successfully removed); * breast cancer diagnosed within the previous 22 years.
overcoming nutritional barriers in hemodialysis patients

Conditions: End Stage Renal Disease

Summary: american hemodialysis patients are frequently malnourished. this contributes to dialysis patient mortality rates that are the highest in the industrialized world at 22% per year. poor nutritional status probably also contributes to high health care costs (an average of two hospitalizations annually per patient and total medicare expenditures of $11 billion per year) and diminished quality of life. the researchers' prior work identified several potentially modifiable nutritional barriers (e.g. poor appetite, inadequate dialysis dose, poor nutritional knowledge, low fluid intake, and needing help shopping and cooking) and pilot tested a promising approach to overcome these barriers. this proposed community-based randomized controlled trial extends the researchers' prior work by targeting specific nutritional barriers with a tailored feedback and education intervention. approximately 40 dialysis facilities in northeast ohio will be randomly assigned to intervention and control groups, with approximately 100 malnourished patients enrolled from 20 intervention facilities and 100 from 20 control facilities. baseline evaluation will include measures of nutritional status, specific barriers, inpatient expenditures, and quality of life. on a monthly basis for 12 months, intervention patients and their dietitians will receive tailored feedback and education on overcoming patient-specific barriers. they will then meet monthly to jointly formulate a care plan addressing these barriers. control patients will continue to get usual care. major analyses will compare changes in nutritional parameters in intervention vs. control patients with adjustment for nesting of patients within facilities. the proposed project will test a novel intervention that targets patients and providers as they together make nutrition-related decisions. overcoming specific barriers may lead not only to improved nutritional status but also to better patient survival, decreased health care costs, and increased quality of life.


Eligibility criteria:
inclusion criteria: * most recent albumin and mean albumin over last 3 months \<3.7 g/dl by bromcresol green method (or \<3.4 g/dl by bromcresol purple method) * age greater than or equal to 18 years * on chronic hemodialysis at least 9 months exclusion criteria: * mentally incompetent * cirrhosis * aids * cancer * terminal illness * malabsorption * receiving total parenteral nutrition
effect of graston technique on planter thickness in patients with planter fasciitis

Conditions: Plantar Fascitis

Summary: this study will be conducted to investigate the effect of graston technique on planter thickness in patients with planter fasciitis

plantar fasciitis (pf), generally a self-limiting condition, is identified as one of the most common causes of heel pain in adults. it affects both sedentary and athletic populations . it may be considered that pf emerges due to excessive and prolonged standing or running, which causes an acute inflammation or micro-tears, and degenerative changes plantar fascia. the persistence of these risk factors inhibits the regular repair process thus collagen degeneration occurs, causing the structural changes of the plantar fascia. numerous interventions have been described for treatment of pf, which include: stretching calf or plantar region which is performed with the patient stands with staggered legs facing toward a wall, with both hands stretched out .the graston technique can break up scar tissue and restore soft tissue. the graston technique is a type of manual therapy in which patented stainless-steel instruments are used to restore soft tissue motion by breaking up scar tissue. fifty patients with planter fasciitis will be assigned randomly to two equal groups; first one will receive graston technique in addition to exercise program, the second one will receive exercise program only for six weeks

Eligibility criteria:
inclusion criteria: * patients that clinically diagnosed cases of plantar fasciitis not less than 6 weeks. * patients willing to precipitate in the study and take treatment for 6 successive weeks. * heel pain felt maximally over the plantar aspect of heel * pain in the heel on the first step in the morning * no history of rest pain in the heel exclusion criteria: * subjects with clinical disorders where therapeutic ultrasound is contraindicated such as infective conditions of foot, tumor, calcaneal fracture, metal implant around ankle. * subjects with a clinical disorder where myofascial release is contraindicated as dermatitis. * subjects with impaired circulation to lower extremities * subjects with referred pain due to sciatica and other neurological disorders. * arthritis * corticosteroids injection in heel preceding 3 months

Keywords: graston technique planter thickness planter fasciitis